This randomized trial demonstrates a framework to enhance capital resilience while reducing carbon intensity by ~30%, implying improved investment viability.
Presented on 21 May 2026: Session 27 Energy incumbents face capital allocation uncertainty as traditional investment heuristics no longer reliably signal long-term bankability. Transition policy, investor taxonomies, and market fragmentation are reshaping how portfolios are financed, sanctioned, and valued. Portfolio-wide carbon intensity has emerged as a first-order risk and value variable, requiring structural portfolio change. This paper introduces a practical framework for portfolio transformation, demonstrated through a case study for a Major targeting ~30% CO2e abatement while maximising commercial value. Moving beyond traditional financial metrics, the framework embeds carbon intensity management and capital resilience throughout the transformation lifecycle by: (1) recognising risk through carbon intensity pathways to quantify exposure, defining intensity-weighted screening criteria; (2) building value by mandating carbon intensity projection, impact modelling, and verification within due diligence and valuation processes; and (3) enabling the vision through governed execution and portfolio-level carbon intensity tracking. Our results demonstrate that establishing target carbon intensity identifies high-risk assets while screening criteria filter targets based on risk profile. Due diligence quantifies carbon intensity impact, and valuation incorporates carbon pricing, showing how lower carbon intensity contributes to commercial attractiveness (~A$86MM portfolio NPV). AI-driven portfolio management systems track reduction progress against targets. By embedding carbon intensity as a core risk and value driver within screening, due diligence, valuation, and governance, we built a ~28% abatement pathway with positive NPV. Further, we show how low carbon intensity or ‘advantaged’ gas can capture greater value for capital resilience during times of transition uncertainty. To access the Oral Presentation click ‘Supplementary data’ below. To read the full paper click here
No takes yet. Share an insight, caveat, or question.
Peter Carydias (2026) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: